▶해외 사업 고성장 전망
Daewoong Pharmaceutical's gastroesophageal reflux treatment (FEXUCLUE, expected to be sold in the fourth quarter of 2022) and diabetes treatment (enavogliflozin, expected to be released in the second half of 2023) are drugs with the latest mechanism of action, and the prescription rate in the related market is increasing.
Daewoong Pharmaceutical's products are expected to increase worldwide market share in a fast-growing market based on brand power and marketing power.
In addition, Nabota(botulinum toxin preparation) was concluded after the lawsuit between Medytox and Evolus, and Strong sales growth in the US market is expected to continue. Exports, which were around KRW 49 billion in 2021, increased to KRW 23 billion in the first quarter of 2022 alone.
Daewoong Pharmaceutical plans to enlarge its established global market including China, Australia, and Europe.
The markets targeted by the new products (FEXUCLUE tablets, and Enavogliflozin) are gastric reflux treatment and type 2 diabetes treatment, which are valued at around US$ 150 million and US$ 526.6 million for each and are growing steadily in terms of chronic disease treatment.
In the same market, fexuclue tablets and Enavogliflozin are showing the effect of increasing efficacy and lowering side effects in areas where existing treatments have not met based on a new mechanism of action. Sales of each product are expected to exceed KRW 60 billion and KRW 40 billion, respectively, in the third year after launch.
by BK Min, KDFN kdf@kdfnews.com